Standard BioTools Inks New Agreement to Sell Mass Cytometry Business for $5.5M
Standard BioTools has entered into a new agreement to sell its mass cytometry business for $5.5 million. This transaction follows a previous attempt to sell the business that fell through. The sale aims to streamline the company's operations and focus on core strategic areas.
Form 4 Standard Biotools Inc For: 30 September By Investing.com
This article announces the filing of a Form 4 for Standard Biotools Inc. for the period ending September 30. It's a brief financial news update from Investing.com, providing basic information about the SEC filing.
Form 4 Standard Biotools Inc For: 30 September By Investing.com
The article reports on a Form 4 filing for Standard Biotools Inc. on September 30. It includes the company's stock performance and general market data from Investing.com. The content primarily serves as an announcement for the filing, with additional financial market information.
Standard BioTools switches Mass Cytometry buyer to Element for $5.5M
Standard BioTools Inc. (NASDAQ:LAB) has terminated its agreement with Multiplex Bio and entered a new definitive agreement to sell its Mass Cytometry Business to Element Biosystems, LLC for $5.5 million in cash. This change increases Standard BioTools' net cash position by approximately $15 million, as it removes the obligation for a $10 million working capital loan required in the previous deal. The transaction is expected to close by the end of 2026, concurrently with Standard BioTools’ merger with Treeline Biosciences.
Standard BioTools Finalizes $5.5M Mass Cytometry Business Sale to Element Biosystems
Standard BioTools Inc. has terminated its prior agreement with Multiplex Bio Inc. to sell its mass cytometry division and instead entered a new $5.5 million cash deal with Element Biosystems, LLC. This change occurred after Standard BioTools received a "Business Superior Proposal" from GMT Venture Partners, Element Biosystems' parent company. The transaction is contingent on shareholder approval and the closing of Standard BioTools' merger with Treeline Biosciences, Inc.
Standard BioTools to Sell Mass Cytometry Business to Element Biosystems for $5.5 Million
Standard BioTools (LAB) has agreed to sell its mass cytometry business to Element Biosystems for $5.5 million in cash, supported by GMT Venture. This decision led to the termination of a prior agreement with Multiplex Bio, for which Standard BioTools will pay a $1.5 million fee, partially covered by GMT Venture. The new deal, which has no financing condition, is contingent on stockholder approval and the completion of Standard BioTools' merger with Treeline Biosciences.
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Standard BioTools has terminated its agreement to sell its Mass Cytometry Business to Multiplex Bio and has entered into a new definitive agreement with Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, for $5.5 million in cash. This change occurred after GMT Venture’s unsolicited proposal was deemed superior, leading to an increase in Standard BioTools' net cash position for its merger with Treeline Biosciences. The Element transaction is expected to close by the end of 2026, concurrently with the Treeline merger, pending stockholder approval.
Standard BioTools Announces Termination of Multiplex Bio Deal, Enters Agreement to Sell Mass Cytometry Business to Element Biosystems Ahead of Treeline Merger
Standard BioTools Inc. has terminated its agreement with Multiplex Bio and instead entered into a definitive agreement to sell its Mass Cytometry Business to Element Biosystems, LLC for $5.5 million in cash. This new deal, spurred by an unsolicited proposal from GMT Venture Partners, is considered superior and will significantly enhance Standard BioTools' cash position by approximately $15 million. The transaction is expected to close by the end of 2026, concurrently with the company's merger with Treeline Biosciences, pending stockholder approval.
Standard BioTools Inc. - Common Stock (Nasdaq:LAB) Detailed Stock Data
This article provides detailed stock data for Standard BioTools Inc. (Nasdaq:LAB), including its current price, trading metrics, and price performance over various periods. As of September 22, 2026, the stock was trading at $0.7498, unchanged, with a 52-week range of $0.6251 to $1.720. The company's shares outstanding are 378,860,686, and its Year-To-Date performance shows a significant decrease of 40.96%.
Standard BioTools (LAB) Short Interest & Short Float | Updated Sep 2026 $LAB
Standard BioTools (LAB) saw an increase in short interest by 23.85% to 2.98 million shares as of August 31, 2026, representing 1.04% of its public float. The short interest ratio (days to cover) for LAB is currently 1.8, indicating it would take less than two days of average trading volume to cover all short positions. This article provides detailed historical short interest data and answers frequently asked questions about LAB's short interest metrics.
Protein Microarray Market Report Examines Industry Trends, Growth Drivers And Future Outlook
The protein microarray market is projected to reach $6.69 billion by 2030, growing at a CAGR of 9.2%, driven by advancements in personalized medicine, drug development, and biomarker discovery. Key players like PerkinElmer, Thermo Fisher Scientific, and Agilent Technologies are prominent, with innovations such as KREX technology and the i-ome discovery platform shaping its future. The market is segmented by type, technology, application, and end-user, reflecting its broad scope and evolving nature.
Standard BioTools (NASDAQ: LAB) exec uses 25.7K shares for taxes
Sean Mackay, SVP & Chief Business Officer at Standard BioTools (NASDAQ: LAB), had 25,729 shares of common stock withheld on August 20, 2026, to cover tax obligations from vested restricted stock units. This transaction, valued at $0.672 per share, resulted in him holding 1,480,823 shares directly afterward. The event is a non-market disposition for tax purposes rather than a sale.
Standard BioTools (LAB) CFO sees stock withheld for taxes
Standard BioTools (LAB) CFO Hanjoon Alex Kim had 28,195 shares of common stock withheld on August 20, 2026, to cover tax withholding obligations from vested restricted stock units. This was a "code F" transaction, meaning the shares were withheld for tax payment rather than sold on the open market. After this transaction, Kim directly holds 2,534,859 shares of Standard BioTools common stock.
Enterprise value to EBIT forward of Standard BioTools Inc. – BX:FLB
This article focuses on the enterprise value to EBIT forward for Standard BioTools Inc. (BX:FLB). It is presented as a financial data point within TradingView's platform, indicating that the content is likely a snippet from a financial analysis tool rather than an in-depth article. The text primarily consists of navigation and disclaimer information from the TradingView website.
Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing
MAK Capital Fund LP, MAK Capital One LLC, and Michael A. Kaufman have filed an amended Schedule 13G, reporting a collective 7.3% ownership stake in Standard BioTools Inc. (LAB). This amounts to 28,813,904 shares of Common Stock, with shared voting and dispositive power among the reporting persons. The filing confirms their passive investment intent, not aimed at changing or influencing company control.
Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake
Long Focus Capital Management, LLC and its controller, John Helmers, have disclosed a 6.0% passive stake in Standard BioTools Inc. (LAB), representing 23,500,000 shares of common stock as of June 30, 2026. This ownership is held on behalf of their clients, with shared voting and dispositive power, and no single client owns more than 5% of the outstanding common stock. The filing indicates a neutral sentiment and impact.
Standard BioTools (NasdaqGS:LAB) Stock Forecast & Analyst Predictions
Standard BioTools (NasdaqGS:LAB) is facing a forecast decline in earnings by 5.8% annually, despite an expected annual revenue growth of 1.8%. The company recently withdrew its 2026 earnings guidance due to a pending merger with Treeline Biosciences and received a Nasdaq non-compliance notice for its share price falling below the minimum bid requirement. Analysts have adjusted price targets several times, reflecting volatility and ongoing strategic changes like divestitures and collaborations, while also noting significant shareholder dilution.
Standard BioTools (LAB) Stock Rebound Leaves Revenue Slide And Losses In Focus
Standard BioTools (LAB) saw a slight stock rebound after its Q2 2026 earnings, but this is overshadowed by a 7.6% revenue decline to US$20.1 million and persistent losses, despite a narrower net loss from continuing operations. The market is waiting for sustained top-line growth to justify its valuation, with both bullish and bearish arguments focusing on the company's ability to leverage mergers and partnerships against ongoing demand and funding challenges.
Standard BioTools Reports Second Quarter 2026 Financial Results
Standard BioTools Inc. announced its financial results for the second quarter of 2026, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, anticipated to close before year-end 2026, and has withdrawn its full-year 2026 revenue outlook due to this pending merger. The results also highlighted improved gross margins driven by productivity enhancements and cost discipline.
Standard BioTools Inc. (LAB) Stock Price, News, Quote & History
This article provides comprehensive financial information for Standard BioTools Inc. (LAB), including its current stock price, historical data, and analyst ratings. It details the company's overview, its segments in proteomics and genomics, key products like the SomaScan platform and CyTOF technology, and financial performance metrics. The article also includes comparisons with similar medical device companies and recent news regarding analyst actions.
STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary
STANDARD BIOTOOLS INC. reported its Q2 2026 results, showing revenue of $20.1M and a diluted loss per share of $(0.07), which indicates an improvement compared to the previous year. Key highlights include an announced merger with Treeline Biosciences, the divestiture of the SomaScan business to Illumina for $388.2M, and significant operational restructuring to reduce costs. The company also saw a decline in total revenue year-over-year but an increase in year-to-date consumables sales.
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss
Standard BioTools (NASDAQ: LAB) reported a revenue decline of 7.6% year-over-year in Q2 2026, reaching $20.1 million, and a widened diluted loss per share from continuing operations. Despite a GAAP net loss increase due to transaction expenses, significant cost reductions and higher gross margins substantially narrowed the adjusted EBITDA loss. The company's revenue contraction affected all categories, and it withdrew its full-year 2026 outlook due to a pending merger with Treeline Biosciences.
Standard BioTools Reports Second Quarter 2026 Financial Results
Standard BioTools Inc. (NASDAQ: LAB) announced its second quarter 2026 financial results, reporting $20.1 million in revenue and an 84% year-over-year improvement in adjusted EBITDA. The company also confirmed that its merger with Treeline Biosciences is progressing and is expected to close before the end of 2026, and it has withdrawn its full-year 2026 revenue outlook due to the pending merger.
Standard BioTools (NASDAQ: LAB) Q2 revenue $20.1M as merger advances
Standard BioTools Inc. (NASDAQ: LAB) reported Q2 2026 revenue of $20.1 million, a 7.6% decrease year-over-year, alongside a narrowing adjusted EBITDA loss to $2.5 million from $16.1 million in Q2 2025. The company is actively moving forward with its merger with Treeline Biosciences and has withdrawn its full-year 2026 revenue outlook due to this pending transaction. Strong liquidity is noted with cash and investments totaling $541.1 million, significantly up from the prior year.
Standard BioTools Number of Employees 2026 | Employee Count & Headcount Data
Standard BioTools, Inc. (LAB) had 357 employees worldwide as of March 2026, a 21.5% decline since 2023. The company, headquartered in Boston, Massachusetts, is actively hiring but saw a 96.8% decline in active job postings in 2026 compared to 2025. Employee sentiment is negative and declining, and the average salary is $117,605 globally.
Standard BioTools Reports Second Quarter 2026 Financial Results
Standard BioTools Inc. announced its Q2 2026 financial results, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, including a planned divestiture of its Mass Cytometry business and Illumina's early buyout of contingent payments, aiming for a close by year-end 2026 to maximize shareholder value. Due to the pending merger, Standard BioTools has withdrawn its full-year 2026 revenue outlook.
Standard BioTools (LAB) CEO has 362,625 shares withheld for taxes
Standard BioTools (LAB) CEO Michael Egholm had 362,625 shares of common stock withheld on August 3, 2026, to cover tax obligations arising from the vesting of restricted stock units granted on August 1, 2025. The shares were valued at $0.868 each for this tax-withholding disposition, which is not an open-market sale. After this transaction, Egholm directly owns 6,235,331 common shares of Standard BioTools.
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Standard BioTools Inc. (NASDAQ: LAB) announced the sale of its Mass Cytometry business to Multiplex Bio and a $30 million buyout from Illumina for contingent payments related to its SomaLogic acquisition. These actions are intended to facilitate its previously announced merger with Treeline Biosciences, which is now proceeding after early termination of the HSR waiting period. The Mass Cytometry sale aims to ensure continued investment and commercialization of its CyTOF and Hyperion product lines under new dedicated leadership.
Standard BioTools Inc. (NASDAQ:LAB) Short Interest Update
Standard BioTools Inc. (NASDAQ:LAB) experienced a significant 35.4% decline in short interest during July, falling to 2.21 million shares by July 15th, representing 0.8% of its shares and a 0.7-day short-interest ratio. Despite institutional investors increasing their stakes, analyst sentiment remains cautious with an average "Reduce" rating and a target price of $1.35. The company's stock trades at $0.86 with a market cap of $337.28 million.
BlackRock (LAB) reports 7.9M-share, 2.0% position in Standard BioTools
BlackRock, Inc. has reported a beneficial ownership of 7,911,347 shares, representing a 2.0% stake in Standard BioTools Inc. This position grants BlackRock sole voting and dispositive power over these shares. The filing, a SCHEDULE 13G/A, indicates that while underlying clients may receive dividends or sale proceeds, no single client holds more than five percent of the company's outstanding common shares.
425 1 ef20078902_425.htm 425 Filed by Standard BioTools Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Standard BioTools Inc. Commission File No.: 001-34180 July 28, 2026 Standard BioToolsMass Cytometry Sale Announcement
Standard BioTools Inc. has announced the sale of its Mass Cytometry business to Multiplex Bio, a company led by advanced imaging industry veterans. The transaction is expected to close by the end of 2026, concurrently with the Treeline transaction, and requires Standard BioTools' shareholder approval. Multiplex Bio aims to become a leader in proteomic detection and imaging by improving form factors, expanding service offerings, developing end-to-end software, and repositioning the brand.
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
Standard BioTools (LAB) announced it has agreed to sell its Mass Cytometry business to Multi. This sale comes amid a pending merger between Standard BioTools and Treeline Biosciences. The full details of the transaction are available with a premium subscription.
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
Standard BioTools has announced the sale of its mass cytometry business to its existing commercial partner, Fluidigm, for $100 million. This divestiture comes as Standard BioTools prepares for its upcoming merger with Treeline Biosciences, a strategic move aimed at focusing the combined company's efforts on high-growth areas within biological tools. The transaction is expected to close in the third quarter of 2026, subject to customary conditions.
Standard BioToolsMass Cytometry Sale Announcement
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio, a company led by advanced imaging industry veterans. The transaction is expected to close by the end of 2026, concurrently with the Treeline transaction, and aims to maintain business continuity for customers and employees. Multiplex Bio plans to become a leader in proteomic detection and imaging by refining their technology, expanding services, developing end-to-end software, and repositioning their brand.
Standard BioTools Sells Mass Cytometry Unit for $5 Million Note and Nets $30 Million From Illumina
Standard BioTools has completed two significant financial maneuvers: selling its mass cytometry business to Multiplex Bio for a $5 million promissory note and potential additional considerations, and receiving approximately $30 million from Illumina. The $30 million from Illumina settles a 2026 earnout waiver and terminates various SOMAmer-related royalty and licensing agreements. These actions are designed to monetize contingent assets, simplify intellectual property relationships, and streamline the company's portfolio in anticipation of its upcoming merger with Treeline.
Standard BioTools (LAB) plans sale of Mass Cytometry business alongside Treeline deal
Standard BioTools Inc. (LAB) announced plans to sell its Mass Cytometry business, including product lines like CyTOF and Hyperion, to Multiplex Bio, a private company led by advanced imaging industry veterans. This divestiture is expected to close by the end of 2026, concurrently with the separate Treeline transaction, and is subject to shareholder approval. Multiplex Bio intends to ensure continuity of operations, maintain customer relationships, and retain most of the current team while planning to enhance mass cytometry technology and expand services for spatial proteomics.
Standard BioTools (NASDAQ: LAB) nets $30M Illumina buyout, sells mass cytometry arm
Standard BioTools Inc. (NASDAQ: LAB) has executed two significant transactions in anticipation of its merger with Treeline Biosciences: it received approximately $30 million from Illumina Inc. to buy out earnout, royalty, and license obligations from Illumina’s acquisition of SomaLogic business, and it agreed to sell its mass cytometry business to Multiplex Bio Inc. for up to $10 million ($5M note plus $5M potential milestone). These strategic moves aim to streamline Standard BioTools' portfolio, enhance its cash position for the Treeline merger, and ensure continued support for its mass cytometry products under new ownership. The sale of the mass cytometry business is expected to close concurrently with the Treeline merger by the end of 2026, subject to stockholder approval and other conditions.
Standard BioTools Announces Sale of Mass Cytometry Business
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio and a $30 million buyout of earnout and royalty payments from Illumina's acquisition of SomaLogic. These actions aim to advance Standard BioTools' merger with Treeline Biosciences, with the Mass Cytometry sale ensuring continuity of its CyTOF and Hyperion product lines under new dedicated leadership. The Treeline merger is also progressing, having received early termination of the Hart-Scott-Rodino waiting period.
Standard BioTools Announces Sale of Mass Cytometry Business
Standard BioTools has announced the sale of its Mass Cytometry business to Multiplex Bio and a $30 million buyout of contingent payments from Illumina related to its SomaLogic acquisition. These transactions are part of Standard BioTools' ongoing merger with Treeline Biosciences, which recently received early termination of the HSR waiting period. The Mass Cytometry sale aims to ensure continuity while the buyout enhances the company's pro forma cash position for the Treeline merger.
Standard BioTools Inc. Revenue Breakdown – NASDAQ:LAB
Standard BioTools Inc. (NASDAQ: LAB) reported a total revenue of $85.33 million USD last year. The "Consumables" segment was the top-performing segment, generating $36.25 million USD. The United States was the largest contributor to revenue, accounting for $28.40 million USD last year, following $89.90 million USD the year prior.
Form 4 Standard Biotools Inc For: 27 July By Investing.com
This article reports on a Form 4 filing for Standard Biotools Inc. on July 27, without providing specific details about the filing. It is a brief news update from Investing.com, noting the company's stock symbol LAB and its percentage change. The core content is very minimal, serving primarily as an announcement of the filing.
Standard BioTools Inc. (LAB) CFO share withholding for tax obligations
Standard BioTools Inc.'s CFO, Kim Hanjoon Alex, reported a tax-withholding disposition of 202,476 shares of common stock on July 23, 2026. This action, valued at $0.895 per share, was taken to cover tax obligations arising from vested restricted stock units. Following this transaction, the CFO directly owns 2,563,054 shares, which includes 5,000 shares acquired through an Employee Stock Purchase Plan.
Standard BioTools Inc (LAB) Income Statement
This article provides a detailed quarterly and annual income statement for Standard BioTools Inc (LAB), presenting its financial performance over several years. It includes metrics such as total revenue, cost of revenue, operating expenses, and net income, alongside percentage changes year-over-year. The document also offers a FAQ section explaining how to interpret the income statement and highlighting key financial metrics for investors.
LAB|Standard BioTools Inc|Price:0.833|Chg%:-0.042
This article provides a detailed overview of Standard BioTools Inc (LAB), including its company background, business scope, financial data, and market performance. The company develops, manufactures, and sells instrumentation, consumables, and services for scientists and biomedical researchers, focusing on proteomics and genomics. It also lists key executives, major shareholders, and institutional holdings, noting that consumables are its biggest revenue source.
Standard BioTools Inc (LAB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Standard BioTools Inc (LAB), including major institutional and individual holdings. It presents data on top shareholders like Casdin Capital, LLC and Viking Global Investors LP, breaks down holdings by shareholder type, and shows institutional shareholding trends over recent quarters. The report also lists shareholder activity with changes in holdings for key investors and related ETF exposures.
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates
Standard BioTools Inc (LAB) has an earnings forecast score of 8.00 and an average price target of $1.55, with a potential upside of 75.32% based on two analyst ratings. Analysts largely recommend a "Buy" for the stock, forecasting next quarter's revenue at $20.80M and EPS at -$0.01. The previous quarter's EPS was $0.05, significantly below the market expectation of $0.33.
Standard BioTools Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Standard BioTools (LAB) received a Nasdaq notice on July 22, 2026, for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has 180 days, until January 19, 2027, to regain compliance. Shares will continue to trade on the Nasdaq Global Select Market, and the company may be eligible for an additional 180-day grace period if it transfers to the Nasdaq Capital Market.
Standard BioTools (NASDAQ: LAB) warned on Nasdaq minimum bid-price compliance
Standard BioTools Inc. (NASDAQ: LAB) received a warning from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement for continued listing, after its stock traded below this level for 30 consecutive business days. The company has 180 calendar days, until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Standard BioTools is exploring options, including a potential reverse stock split, to resolve the non-compliance.
LAB|Standard BioTools Inc|Price:0.852|Chg%:-0.024
This article provides a detailed analysis of Standard BioTools Inc. (LAB) through TradingKey's stock score, highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Healthcare Equipment & Supplies industry. Despite strong market performance, technicals suggest a sideways trading pattern between support and resistance levels. The company's strengths include being in a growing phase with a high institutional ownership, while its P/E ratio indicates it may be overvalued.
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Standard BioTools Inc. announced the filing of a registration statement on Form S-4 with the SEC in connection with its merger agreement with Treeline Biosciences, Inc. The combined company, to be named Treeline Biosciences Holdings, Inc., is expected to have over $900 million in cash at closing and a deep clinical-stage pipeline. The filing highlights promising Phase 1 monotherapy data for Treeline's TLN-121 in lymphoma, with an 84% overall response rate, and the appointment of Sue Desmond-Hellmann to Treeline's Board of Directors.
